TEVA

Quote

Short

News

Articles

Message Board

Teva, Sanofi report durable phase 2b efficacy for duvakitug in ulcerative colitis, Crohn's disease

February 17, 2026 06:15:51 am

Source: SeekingAlpha

2026-02-17 06:15:51 ET

Read the full article on Seeking Alpha

For further details see:

Teva, Sanofi report durable phase 2b efficacy for duvakitug in ulcerative colitis, Crohn’s disease

Teva Pharmaceutical Industries Limited American Depositary Shares

NASDAQ: TEVA

TEVA Trading

-2.39% G/L:

$28.7801 Last:

3,213,532 Volume:

$29.38 Open:

mwn-app Ad 300

TEVA Latest News

March 06, 2026 02:20:00 pm

The 3 Best Stocks to Invest $1,000 in Right Now

March 04, 2026 02:07:00 pm

Forget Teva: This Dividend Top Dog Is the Real Value Buy Today

March 04, 2026 04:26:00 am

Billionaire Stanley Druckenmiller Dumped 2 of His Top Performers -- Teva and Taiwan Semiconductor -- and Made This Sector-Based ETF His Fund's New No. 2 Holding

March 03, 2026 05:00:00 pm

Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug

TEVA Stock Data

Market Cap $39,421,335,208

Float 1,138,314,769

Insiders Ownership 0.04%

Institutions 264

Short Percent N/A

Industry Pharmaceuticals

Sector Healthcare

Website https://www.tevapharm.com

Country IL

City Tel Aviv

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App